Diabetes mainstay metformin tamps down lung inflammation in COVID models

The 27-year-old diabetes drug metformin has been studied for its potential use in a wide range of other disorders, including heart disease and cancer. Now researchers led by the University of California, San Diego, say the diabetes mainstay might help prevent lung inflammation in patients with COVID-19.